3. Learning Objectives

4. PLATO Primary Efficacy End Point CV Death, MI, or Stroke

5. TRACER Primary End Point Composite of CV Death, MI, Stroke, Hospitalization for Ischemia, Urgent Revascularization

6. CHARISMA

8. Bleeding Trends in PCI

9. Major Bleeding at Access Sites Pooled Analysis of Bivalirudin Studies

10. TRITON-TIMI 38

11. ATLAS ACS 2—TIMI 51 Mortality Benefit With Very-Low-Dose Rivaroxaban in STEMI Patients

13. TRILOGY-ACS Primary Efficacy End Point to 30 Months (Age < 75 years)

15. TRILOGY-ACS Subgroup Analysis in Patients With Non-STEMI ACS

17. ACUITY Intraprocedural Thrombotic Events (IPTE*)

18. Intraprocedural Stent Thrombosis During PCI

19. EUROMAX Stent Thrombosis With Bivalirudin Treatment

20. RAPID Patients With Residual Reactivity Over Time

22. CHAMPION PLATFORM

23. CHAMPION PCI

24. CHAMPION PHOENIX Primary Efficacy Outcomes at 48 Hours, MITT

25. Third Universal Definition of MI

26. Abbreviations

27. Abbreviations (cont)

28. References

29. References (cont)

30. References (cont)

31. References (cont)

32. References (cont)

33. References (cont)

34. References (cont)

35. References (cont)